Semaphoring mAb: a New Guide in RIT in Inhibiting the Proliferation of Human Skin Carcinoma

  • Liu, Yuan (Department of Dermatovenereology, Tianjin Medical University General Hospital) ;
  • Ma, Jing-Yue (Department of Dermatovenereology, Tianjin Medical University General Hospital) ;
  • Luo, Su-Ju (Department of Dermatovenereology, Tianjin Medical University General Hospital) ;
  • Sun, Chen-Wei (Department of Dermatovenereology, Tianjin Medical University General Hospital) ;
  • Shao, Li-Li (Department of Dermatovenereology, Tianjin Medical University General Hospital) ;
  • Liu, Quan-Zhong (Department of Dermatovenereology, Tianjin Medical University General Hospital)
  • Published : 2015.03.04


Semaphoring is a transmembrane receptor which participates in many cytokine-mediated signal pathways that are closely related to the angiogenesis, occurrence and development of carcinoma. The present study was designed to access the effect of mono-antibody (mAb) guided radioimmunotherapy (RIT) on skin carcinoma and investigate the potential mechanisms. Semaphoring mAb was acquired from mice (Balb/c), purified with rProtein A column; purity, concentration and activity were tested with SDS-PAGE and indirect ELISA; specificity and expression on the cutanuem carcinoma line and tissue were tested by Western blotting; morphology change was assessed by microscopy. MTT assay and colony inhibition tests were carried out to test the influence on the proliferation of tumor cells; Western blotting was also carried out for expression of apoptosis-associated (caspase-3, Bax, Bcl-2) and proliferation-related (PI3K, p-Akt, Akt, p-ERK1/2, ERK1/2) proteins and analyse the change in signal pathways (PI3K/Akt and MEK/ERK). The purity of purified semaphorin mAb was 96.5% and the titer is about $1{\times}10^6$. Western blotting showed semaphoring mAb to have specifically binding stripes with semaphoring b1b2 protein, B16F10, and A431 cells at 39KDa, 100KDa and 130KDa, respectively. Positive expression was detected both in cutanuem carcinoma line and tissue and it mostly located in cell membranes. MMT assay revealed dose-relate and time-relate inhibitory effect of semaphorin mAb on A431 and B16F10. Colony inhibition tests also showed dose-relate inhibitory effects. Western blotting demonstrated the expression of apoptosis and proliferation-related protein and changes in signal pathway. In conclusion, we demonstrated that semaphorin is highly expressed on the tumor cell-surfaces and RIT with semaphorin mAb has effect in i nhibiting proliferation and accelerating apoptosis of tumor cells.


  1. Abbasakoor F, Woodhams J, Farooqui N, et al (2013). Safe ablation of the anal mucosa and perianal skin in rats using photodynamic therapy-a promising approach for treating anal intraepithelial Neoplasia. Photodiagnosis Photodyn Ther, 10, 566-74.
  2. Al-Ejeh F BM (2011). Combined Modality Therapy: Relevance for Targeted Radionuclide Therapy., Philadelphia: Lippincott, Williams & Wilkinson.
  3. Al-Ejeh F, Kumar R, Wiegmans A, et al (2010). Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene, 29, 6085-98.
  4. Bartkova J, Horejsi Z, Koed K, et al (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434, 864-70.
  5. Bouilhol G, Ayadi M, Rit S, et al (2013). Is abdominal compression useful in lung stereotactic body radiation therapy? A 4DCT and dosimetric lobe-dependent study. Phys Med, 29, 333-40.
  6. Cagnoni G, Tamagnone L (2013). Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression. Oncogene, 33, 4795-802
  7. El-Domyati M, El-Ammawi TS, Medhat W, et al (2013). Expression of p53 protein after nonablative rejuvenation: the other side of the coin. Dermatol Surg, 39, 934-43.
  8. Frost SH, Back T, Chouin N, et al (2013). Comparison of 211At- PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm, 28, 108-14.
  9. Fujiwara K, Koyama K, Suga K, et al (2014). Combination radioimmunotherapy using 90Y labeled anti-ROBO1 IgG and chemotherapy improves survival rate of small cell lung cancer xenograft models. J Nucl Med Meeting Abstracts, 55, 1487-.
  10. Grunberg J, Lindenblatt D, Dorrer H, et al (2014). Anti- L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. Eur J Nucl Med Mol Imaging, 41, 1907-15.
  11. Guo Y, Parry JJ, Laforest R, et al (2013). The role of p53 in combination radioimmunotherapy with 64Cu-DOTAcetuximab and cisplatin in a mouse model of colorectal cancer. J Nucl Med, 54, 1621-9.
  12. Hohloch K, Lankeit HK, Zinzani PL, et al (2014). Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. Eur J Nucl Med Mol Imaging, 41, 1585-92.
  13. Jandl T, Revskaya E, Jiang Z, et al (2013). Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. Nucl Med Biol, 40, 177-81.
  14. Kohno M, Ohara K, Horibe T, et al (2014). Inhibition of Neurite Outgrowth by a Neuropilin-1 Binding Peptide Derived from Semaphorin 3A. Interl J Peptide Res Therapeut, 20, 153-60.
  15. Kovtun YV, Audette CA, Ye Y, et al (2006). Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res, 66, 3214-21.
  16. Muratori C, Tamagnone L (2012). Semaphorin signals tweaking the tumor microenvironment. Adv Cancer Res, 114, 59-85.
  17. Nasarre P, Gemmill RM, Potiron VA, et al (2013). Neuropilin-2 Is upregulated in lung cancer cells during TGF-beta1-induced epithelial-mesenchymal transition. Cancer Res, 73, 7111-21.
  18. Nehil M, Paquette J, Tokuyasu T, et al (2013). High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphorin 3A. Oncogene, 33, 5151-62
  19. Rehman M, Tamagnone L (2013). Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin Cell Dev Biol, 24, 179-89.
  20. Sharkey RM, Goldenberg DM (2013). Antibody-targeted therapeutic radionuclides in the management of colorectal cancer. in 'Nuclear Medicine Therapy', Eds Springer, 207-37
  21. Sommer G, Rossa C, Chi AC, et al (2011). Implication of RNAbinding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells. PLoS One, 6, 25402.
  22. Song H, Sgouros G (2011). Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv, 8, 26-44.
  23. Staudacher AH, Al-Ejeh F, Fraser CK, et al (2014). The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB (R). EJNMMI Res, 4, 2.
  24. Suzuki T, Hirakawa S, Shimauchi T, et al (2014). VEGF-A promotes IL-17A-producing gammadelta T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells. J Dermatol Sci, 74, 116-24.
  25. Tamagnone L (2012). Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell, 22, 145-52.
  26. Trotta R, Vignudelli T, Candini O, et al (2003). BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell, 3, 145-60.